Merck snares NovaCardia in $350M buyout

Merck has bolstered its cardiovascular pipeline with a deal to buy NovaCardia for $350 million in cash. For Merck, the acquisition marks another step down its five-year plan to restructure the company. Buying up new therapies in development is a key part of that effort, and the competition for acquisitions has been steadily driving up valuations in the biotech world. NovaCardia has a drug--KW-3902--in late-stage studies for congestive heart failure.

"This acquisition continues to deliver on our strategy of targeted acquisitions in areas of unmet medical need in the therapeutic areas of strategic importance for Merck, such as cardiovascular diseases," said Richard Kender, vice president of business development and corporate licensing at Merck.

- check out Merck's announcement
- here's the AP report on the buyout

Related Articles:
Analysts cheer signs of turnaround at Merck. Report
Merck touts reorganization effort. Report
NovaCardia, Quark Biotech file for $86M IPOs. Report
NovaCardia pockets $48M in second round. Report

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

ATAI Life Sciences is topping off a busy year with a $125 million financing, which will push two programs through phase 2 readouts.

After more than a decade working on heart failure programs with Cytokinetics, Amgen is handing two programs back to its partner.